In this video, health care analysts David Williamson and Max Macaluso discuss Dendreon's upcoming third-quarter earnings. David highlights what investors need to look for in the company's press release -- and more importantly, the conference call. Watch and be prepared for Friday's big news.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Quarterly earnings are almost upon us.
David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Medivation, Inc.
MDVN
Johnson & Johnson
JNJ
$149.81
(-0.61%)
$0.92
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
1 Undervalued Growth Stock That Could Go Parabolic Soon
Why Scholar Rock Shares Are Soaring Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.